Cargando…

Currently available drugs for the treatment of Coronavirus-2

The Coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome Coronavirus 2 (SARS CoV-2) has created a never-before-seen problem for humanity. The world was pushed into a position where we needed to identify the effective drugs for a disease that has unknown...

Descripción completa

Detalles Bibliográficos
Autores principales: Anbarasan, T., Sahu, Gaurav, Goyal, Abhishek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300456/
http://dx.doi.org/10.1016/B978-0-323-91172-6.00018-2
_version_ 1784751214941962240
author Anbarasan, T.
Sahu, Gaurav
Goyal, Abhishek
author_facet Anbarasan, T.
Sahu, Gaurav
Goyal, Abhishek
author_sort Anbarasan, T.
collection PubMed
description The Coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome Coronavirus 2 (SARS CoV-2) has created a never-before-seen problem for humanity. The world was pushed into a position where we needed to identify the effective drugs for a disease that has unknown characteristics in the early 2020s. SARS CoV-2 Virology research suggested that several drugs could be the potential targets. Remdesivir was the first drug that was shown to have promising results in in vitro studies. Remdesivir became the first antiviral drug approved by USFDA for the management of COVID-19. But later studies show equivocal results. For this entirely new disease, we are still searching the perfect drug. Many existing drugs have been repurposed (steroids, anticoagulation, hydroxychloroquine) with varying success. Many new drugs have been researched for the management of this menace. In this review, we will discuss the mechanisms, uses, dosage, duration, and adverse effects of drugs used in COVID-19.
format Online
Article
Text
id pubmed-9300456
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-93004562022-07-21 Currently available drugs for the treatment of Coronavirus-2 Anbarasan, T. Sahu, Gaurav Goyal, Abhishek Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 Infection Article The Coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome Coronavirus 2 (SARS CoV-2) has created a never-before-seen problem for humanity. The world was pushed into a position where we needed to identify the effective drugs for a disease that has unknown characteristics in the early 2020s. SARS CoV-2 Virology research suggested that several drugs could be the potential targets. Remdesivir was the first drug that was shown to have promising results in in vitro studies. Remdesivir became the first antiviral drug approved by USFDA for the management of COVID-19. But later studies show equivocal results. For this entirely new disease, we are still searching the perfect drug. Many existing drugs have been repurposed (steroids, anticoagulation, hydroxychloroquine) with varying success. Many new drugs have been researched for the management of this menace. In this review, we will discuss the mechanisms, uses, dosage, duration, and adverse effects of drugs used in COVID-19. 2022 2022-07-15 /pmc/articles/PMC9300456/ http://dx.doi.org/10.1016/B978-0-323-91172-6.00018-2 Text en Copyright © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Anbarasan, T.
Sahu, Gaurav
Goyal, Abhishek
Currently available drugs for the treatment of Coronavirus-2
title Currently available drugs for the treatment of Coronavirus-2
title_full Currently available drugs for the treatment of Coronavirus-2
title_fullStr Currently available drugs for the treatment of Coronavirus-2
title_full_unstemmed Currently available drugs for the treatment of Coronavirus-2
title_short Currently available drugs for the treatment of Coronavirus-2
title_sort currently available drugs for the treatment of coronavirus-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300456/
http://dx.doi.org/10.1016/B978-0-323-91172-6.00018-2
work_keys_str_mv AT anbarasant currentlyavailabledrugsforthetreatmentofcoronavirus2
AT sahugaurav currentlyavailabledrugsforthetreatmentofcoronavirus2
AT goyalabhishek currentlyavailabledrugsforthetreatmentofcoronavirus2